
sNDA for Roflumilast Cream 0.05% for the Treatment of AD in Children Aged 2 to 5 Years Gets FDA Nod
The FDA today accepted a supplemental New Drug Application (sNDA) for roflumilast cream 0.05% (Zoryve; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis (AD) in children aged 2 to 5 years, according to a news release from …